Results 171 to 180 of about 1,273,827 (295)

Conformational Restriction of Designer Drugs Reveals Subtype-Selective and Biased CB₂ Agonists with Neuroprotective Effects. [PDF]

J Med Chem
Gioé-Gallo C, Ortigueira S, Prieto-Díaz R, Contino M, Azuaje J, Perrone MG, Riganti C, Alberga D, Mangiatordi GF, Andújar-Arias A, García-Rey A, Graziano G, Stefanachi A, Val C, Martínez AL, Rebassa JB, Reza D, Selas A, Francavilla F, Paleo MR, García-Mera X, Loza MI, Navarro G, Brea J, Sotelo E.   +24 more
europepmc   +1 more source

Designer drugs and sexual dysfunction. [PDF]

Cent European J Urol, 2015
Benyó M.
europepmc   +1 more source

Gut microbiota alterations in patients with non‐small‐cell lung cancer undergoing chemoradiotherapy

Molecular Oncology, EarlyView.
We investigated the impact of concurrent chemoradiotherapy (CRT) on the gut microbiota in patients with locally advanced non‐small‐cell lung cancer. Overall gut microbiota composition remained largely stable throughout CRT while antibiotic exposure may influence microbial diversity.
Hanne Marte Nymoen, Zhi Zhao, Henrik Horndalsveen, Maria Moksnes Bjaanæs, Bjørn Henning Grønberg, Tarje Halvorsen, Tesfaye Madebo, Marianne Aanerud, Jussi Koivunen, Kersti Oselin, Saulius Cicenas, Nina Helbekkmo, Jarkko Ahvonen, Maria Silvoniemi, Tine Norman Alver, Tonje Dalen, Åsa Kristina Öjlert, Saima Jamil Farooqi, Åslaug Helland, Vilde Drageset Haakensen   +19 more
wiley   +1 more source

Polydrug fatal intoxication involving MDPHP: Detection and in silico investigation of multiple 3,4-methylenedioxy-derived designer drugs and their metabolites. [PDF]

J Anal Toxicol
Casati S, Ravelli A, Dei Cas M, Bergamaschi RF, Vanerio S, Sicuro L, Faraone C, Rossi M, Galante N, Mollica L, Roda G, Rota P, Battistini A.   +12 more
europepmc   +1 more source

The newest cathinone derivatives as designer drugs: an analytical and toxicological review. [PDF]

Forensic Toxicol, 2018
Majchrzak M, Celiński R, Kuś P, Kowalska T, Sajewicz M.   +4 more
europepmc   +1 more source

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source

Sublethal Concentrations of 2C-I and 25I-NBOMe Designer Drugs Impact <i>Caenorhabditis elegans</i> Development and Reproductive Behavior. [PDF]

Int J Mol Sci
Gil-Martins E, Barbosa DJ, Cagide F, Remião F, Borges F, Silva R.   +5 more
europepmc   +1 more source

Designer Drugs: A Synthetic Catastrophe. [PDF]

J Reward Defic Syndr, 2015
Fratantonio J, Andrade L, Febo M.
europepmc   +1 more source

A role for eIF5A in translational control of stress‐inducible proteins in multiple myeloma cell lines

Molecular Oncology, EarlyView.
Loss of eIF5A rewires thapsigargin‐mediated endoplasmic reticulum stress responses in multiple myeloma cells by selective translation of mRNA transcripts, consequently dampening thapsigargin‐induced unfolded protein response (UPR) activation and shifting the balance from induction of apoptosis toward cell survival and proliferation.
Demi Both, Ingrid A. M. Derks, Raphaël Vanleyssem, Marine Leclercq, Najla El Hachem, Pierre Close, Eric Eldering, Marco Vincent Haselager   +7 more
wiley   +1 more source

Detection and identification of designer drugs by nanoparticle-based NMR chemosensing. [PDF]

Chem Sci, 2018
Gabrielli L, Rosa-Gastaldo D, Salvia MV, Springhetti S, Rastrelli F, Mancin F.   +5 more
europepmc   +1 more source